← The Wire
CAPRNasdaq
CAPRICOR THERAPEUTICS, INC.
Pharmaceutical Preparations · DE · CIK 1133869
Develops cell and exosome-based therapeutics for Duchenne muscular dystrophy and other diseases
$1.49B
Market cap
$23.80
Last close
-10.0%
1D
-18.9%
5D
3.2M
Volume
Price · last 39 sessions-29.0%
May 4L $23.80 · H $34.38Jun 29
377
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
8-KCompany UpdateJun 26, 20268-KShareholder VoteJun 8, 202610-Q10-QMay 13, 20268-KResults of OperationsMay 12, 20268-KReg FD Disclosure · Company UpdateMay 7, 2026DEF 14ADEF 14AApr 10, 202610-K10-KMar 17, 20268-KResults of OperationsMar 12, 20268-KReg FD Disclosure · Company UpdateMar 10, 2026424B5424B5Dec 5, 20258-KReg FD Disclosure · Company UpdateDec 5, 2025424B5424B5Dec 4, 20258-KReg FD DisclosureDec 3, 20258-KReg FD Disclosure · Company UpdateDec 3, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KReg FD DisclosureJul 11, 20258-KExecutive Change · Shareholder VoteMay 27, 202510-Q10-QMay 14, 20258-KResults of OperationsMay 13, 2025DEF 14ADEF 14AApr 8, 20258-KExecutive ChangeApr 8, 202510-K10-KMar 26, 20258-KResults of OperationsMar 19, 20258-KReg FD DisclosureMar 4, 20258-KCompany UpdateJan 2, 202510-Q10-QNov 14, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 12, 2024SC 13GSC 13GOct 24, 2024424B5424B5Oct 17, 20248-KMaterial Agreement · Reg FD DisclosureOct 17, 2024424B5424B5Oct 16, 20248-KResults of Operations · Company UpdateOct 16, 20248-KReg FD Disclosure · Company UpdateOct 9, 20248-KReg FD DisclosureSep 24, 20248-KMaterial Agreement · Equity IssuanceSep 17, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 7, 20248-KBylaw AmendmentMay 15, 20248-KShareholder VoteMay 15, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 13, 20248-KReg FD DisclosureApr 29, 2024DEF 14ADEF 14AApr 1, 202410-K10-KMar 11, 20248-KResults of OperationsFeb 29, 2024SC 13GCAPRICOR THERAPEUTICS, INC.Feb 7, 20248-KCompany UpdateJan 11, 20248-KCompany UpdateDec 11, 202310-Q10-QNov 14, 20238-KResults of OperationsNov 14, 2023SC 13GSC 13GOct 17, 2023424B5424B5Sep 29, 20238-KMaterial Agreement · Reg FD DisclosureSep 29, 20238-KReg FD Disclosure · Company UpdateSep 29, 20238-KExecutive ChangeSep 6, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 7, 20238-KExecutive ChangeJul 24, 20238-KExecutive ChangeJul 13, 20238-K/ABylaw AmendmentJun 15, 20238-K/AShareholder VoteJun 15, 20238-KBylaw AmendmentJun 13, 20238-KShareholder VoteJun 13, 202310-Q10-QMay 12, 20238-KResults of OperationsMay 11, 2023DEF 14ADEF 14AApr 17, 202310-K10-KMar 17, 20238-KResults of OperationsMar 15, 20238-KMaterial AgreementFeb 16, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 202210-Q10-QAug 12, 20228-KResults of OperationsAug 10, 20228-KCompany UpdateJul 19, 20228-KReg FD DisclosureJun 29, 20228-KShareholder VoteJun 7, 2022
Insider Activity
In the 90 days to Jun 25, 2026: 2 sold $1.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Krasney KarenEVP, GENERAL COUNSEL | Sell | 24,100 | $30.38 | $732K |
| Jun 25, 2026 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | Sell | 24,100 | $30.38 | $732K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance